Open an account

Aytu Biopharma

AYTU · NASDAQ

$2.01+$0.05 (+2.55%)TodayMarket closed ·
Prev close $1.96

About AYTU

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. The company is headquartered in Denver, Colorado and currently employs 82 full-time employees. The company went IPO on 2017-10-20. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.

Employees
82
Headquarters
Denver, Colorado
Listed
Oct 20, 2017
Sector
Health Care
Industry
Pharmaceuticals
Website
aytubio.com

AYTU key statistics

Market cap
21.84M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
51.12K
Volume
7.46K
Open price
$1.97
High today
$2.01
Low today
$1.97
52 Week high
$3.07
52 Week low
$1.80

Aytu Biopharma (AYTU) at a glance

Aytu Biopharma (AYTU) last traded at $2.01, with a market cap of 21.84M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.97 and $2.01. The current price is 2.0% above the day's low and 0.0% below its high.

Volume so far is 7.46K shares, below the average of 51.12K shares a day.

Over the past year Aytu Biopharma has ranged from $1.80 to $3.07, and now sits 17% of the way up that range.

Aytu Biopharma met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.001 per share against an estimate of -$0.3315.

The average analyst price target is $9.86, 390.5% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $9.86
Low
$7.07
Now
$2.01
High
$15.75

AYTU earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 115.4% on average.

  1. Q3 FY24: reported -$0.52 per share against an estimate of -$0.6528
  2. Q4 FY24: reported -$0.82 per share against an estimate of -$0.459
  3. Q1 FY25: reported $0.44 per share against an estimate of -$0.3468
  4. Q2 FY25: reported -$0.26 per share against an estimate of -$0.2856
  5. Q3 FY25: reported $0.21 per share against an estimate of -$0.1734
  6. Q4 FY25: reported -$2.92 per share against an estimate of -$0.0374
  7. Q1 FY26: reported -$0.53 per share against an estimate of -$0.5202
  8. Q2 FY26: reported -$0.001 per share against an estimate of -$0.3315

AYTU news

  • Insights into Aytu BioPharma's Upcoming Earnings

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Earnings Outlook For Aytu BioPharma

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Aytu BioPharma's Earnings: A Preview

Similar companies

Companies in the same industry as Aytu Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.